☆ 4.7 Review

Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis

EUROPEAN JOURNAL OF CANCER (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review

C. Corti et al.

Summary: This systematic review investigates the immunogenicity of COVID-19 vaccines in patients with cancer (PsC). The results show that vaccination against COVID-19 is generally safe and immunogenic for PsC. However, the seroconversion rate in PsC is lower, lagged, or both compared to the general population. Patients with hematologic malignancies, especially those receiving B-cell-depleting agents in the past 12 months, are at the highest risk of poor seroconversion.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Hematology

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia (CLL) have impaired antibody response to COVID-19 vaccination. A third dose of the vaccine can improve the antibody response in some CLL patients. Patients on active treatment and those recently treated with anti-CD20 therapy have lower antibody response rates.

BLOOD (2022)

添加到收藏夹

Article Hematology

Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response

Patrick Reimann et al.

Summary: Patients with haemato-oncological malignancies have lower response rates to COVID-19 vaccination, with a heterologous booster vaccination showing promise in improving response rates, although efficacy varies and may result in mild adverse events.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres

Ondrej Susol et al.

Summary: The mRNA COMIRNATY vaccine has been administered to 392 patients with a two-dose regimen, resulting in an overall antibody response of 70%. The initial results of administering a third dose to 80 patients who did not achieve seroconversion or had a weak response show promise, especially for patients on anti-CD38 therapy.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

添加到收藏夹

Letter Oncology

Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer

Lauren C. Shapiro et al.

CANCER CELL (2022)

添加到收藏夹

Article Oncology

Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer

Vivek Naranbhai et al.

Summary: Patients with cancer have impaired immune responses to SARS-CoV-2 vaccines, and the type and timing of vaccination affect the breadth of immune responses against variants. Concentrations of anti-spike protein antibodies serve as a good surrogate for breadth, and booster doses increase the breadth of immune responses against variants.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients

Lorenzo Canti et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia

Yoshinobu Konishi et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Immune responses following third COVID-19 vaccination are reduced in patients with hematological compared to patients with solid cancer

Annika Fendler et al.

CANCER CELL (2022)

添加到收藏夹

Article Infectious Diseases

The effect of a third-dose BNT162b2 vaccine on anti-SARS-CoV-2 antibody levels in immunosuppressed patients

Esther Saiag et al.

Summary: Most immunosuppressed patients showed an increase in antibody levels after receiving a third dose of the Pfizer-BioNTech vaccine, although the response varied based on the type of disease and level of immunosuppression.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Review Oncology

Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis

Andrea Becerril-Gaitan et al.

Summary: Patients with cancer have impaired immune response to COVID-19 vaccination compared with controls, with lower seroconversion rates and higher likelihood of SARS-CoV-2 infection.

EUROPEAN JOURNAL OF CANCER (2022)

添加到收藏夹

Review Infectious Diseases

Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis

Caifang Zheng et al.

Summary: A meta-analysis showed that COVID-19 vaccines have high efficacy in real-world settings, providing significant protection against SARS-CoV-2-related diseases. Fully vaccinated individuals had vaccine effectiveness of 89.1% against infection, 97.2% against hospitalization, 97.4% against ICU admission, and 99.0% against death.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Oncology

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

Valerie Gounant et al.

Summary: The study found that SARS-CoV-2 vaccines were effective in patients with thoracic cancer, with the majority being immunized after two doses. Administering a third vaccine dose to 1% of patients with persistently low antibody titers resulted in an 88% immunization rate.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment

Yakir Rottenberg et al.

JAMA ONCOLOGY (2022)

添加到收藏夹

Article Oncology

SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents

Charlotte Fenioux et al.

Summary: This study aimed to assess the immune humoral response to the BNT162b2 vaccine in patients treated with anticancer agents. The results showed that the majority of patients had a good humoral response 28 days after the second dose of vaccine, but it gradually decreased over time. The study also found that the time between vaccine and chemotherapy did not interfere with the humoral response.

JAMA ONCOLOGY (2022)

添加到收藏夹

Review Immunology

Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis

Orly Efros et al.

Summary: Solid organ transplant recipients show improved immunogenicity and safety after receiving a third dose of the COVID-19 mRNA vaccine, but a significant portion of patients remain seronegative.

VACCINES (2022)

添加到收藏夹

Editorial Material Hematology

Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia

Cristina Bagacean et al.

BLOOD ADVANCES (2022)

添加到收藏夹

Letter Oncology

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

Muhammad Bilal Abid et al.

CANCER CELL (2022)

添加到收藏夹

Letter Oncology

Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination

Sidse Ehmsen et al.

CANCER CELL (2022)

添加到收藏夹

Letter Hematology

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation

Sigrun Einarsdottir et al.

HAEMATOLOGICA (2022)

添加到收藏夹

Review Medicine, General & Internal

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

Ainsley Ryan Yan Bin Lee et al.

Summary: This systematic review and meta-analysis compared the efficacy of covid-19 vaccines between immunocompromised and immunocompetent individuals. The results showed that immunocompromised patients, especially organ transplant recipients, had significantly lower rates of seroconversion after covid-19 vaccination. A second dose of the vaccine consistently improved seroconversion in all patient groups, although the improvement was smaller for organ transplant recipients. Targeted interventions, including a third dose (booster) of the vaccine, should be performed for immunocompromised patients.

BMJ-BRITISH MEDICAL JOURNAL (2022)

添加到收藏夹

Review Immunology

Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety

Ainsley Ryan Yan Bin Lee et al.

Summary: This study conducted a systematic review and meta-analysis on the efficacy of COVID-19 booster vaccines. The results showed that booster doses are effective in inducing seroconversion in non-responders and are not associated with major adverse events.

VACCINES (2022)

添加到收藏夹

Review Immunology

COVID-19 in Immunocompromised Hosts: What We Know So Far

Monica Fung et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to significant morbidity and mortality globally. The impact of the disease on immunosuppressed patients, such as cancer patients and transplant recipients, remains unclear. Further research is needed to determine the risk of COVID-19 severity and death in immunocompromised patients.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)?

Georgios Chamilos et al.

Summary: Not all cancer patients are equally at risk for severe COVID-19 complications, as factors other than cancer or its treatment may play a significant role. Further research is needed to understand the impact of COVID-19 on this heterogeneous population of patients.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Review Oncology

Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies

Aakash Desai et al.

Summary: The analysis of 2922 cancer patients with COVID-19 from primarily inpatient studies showed a 30-day mortality rate of 30%, while the overall rate was 15% among 624 patients from studies including both inpatient and outpatient populations. Factors such as male sex, older age, cancer subtype, and recent active cancer therapy partially explained the heterogeneity in mortality reporting, with male sex and an interaction between patient age and recent therapy accounting for most of the variance in mortality rates between studies.

CANCER (2021)

添加到收藏夹

Article Oncology

Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

Tania Buttiron Webber et al.

Summary: Chemotherapy, targeted therapy, hormone therapy, lymphocyte count < 1 x 109/ L, and increasing age predict poor seroconversion after two doses of BNT162b2 in up to 20% of patients, indicating the need for a third dose and long-term serological testing in non-responders. Adverse events following immunisation occur much more frequently in women and younger subjects who may benefit from preventive medications.

EUROPEAN JOURNAL OF CANCER (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

Rachna T. Shroff et al.

Summary: Cancer patients showed diminished immune responses to the BNT162b2 mRNA vaccine compared to the control group, but a third dose of the vaccine was found to be safe and significantly improved humoral immunity against SARS-CoV-2.

NATURE MEDICINE (2021)

添加到收藏夹

Review Oncology

COVID-19 vaccines for patients with cancer: benefits likely outweigh risks

Joyce K. Hwang et al.

Summary: Within less than a year of the COVID-19 pandemic, ten vaccines for SARS-CoV-2 have been approved, with two mRNA-based vaccines showing promising results. Concerns arise about the safety and efficacy of these vaccines for cancer patients undergoing immunomodulatory treatments, but most cancer therapies should not hinder the generation of protective immunity. Additional research in this area is needed and it is recommended that the majority of cancer patients receive COVID vaccinations when possible.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Review Infectious Diseases

COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients

Jennifer A. Belsky et al.

Summary: Severe COVID-19 caused by SARS-CoV-2 has a greater impact on immunocompromised patients such as cancer and solid organ transplant recipients, leading to higher comorbidities and poorer hospital outcomes. However, hematopoietic cell transplant recipients and pediatric cancer patients tend to have clinical presentations and outcomes similar to the general population.

JOURNAL OF INFECTION (2021)

添加到收藏夹

Editorial Material Hematology

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT

Rabah Redjoul et al.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Oncology

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar et al.

Summary: Most cancer patients show high seroconversion rates after receiving COVID-19 vaccines, but those with hematologic malignancies, especially after highly immunosuppressive therapies, exhibit lower conversion rates. Patients on immune checkpoint inhibitor therapy or hormonal therapy display high conversion rates.

CANCER CELL (2021)

添加到收藏夹

Letter Oncology

Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies

Lee Greenberger et al.

CANCER CELL (2021)

添加到收藏夹

Review Oncology

Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients

Manit K. Gundavda et al.

Summary: The safety and efficacy of COVID-19 vaccines in cancer patients remain limited, but may be extrapolated from clinical trials and population data. Concerns about efficacy due to variable immune response and immunosuppression in cancer patients may impact vaccine effectiveness.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement

Matthew J. Page et al.

Summary: The study provides an overview of the processes used to update the PRISMA 2009 statement, including a survey of systematic review methodologists and journal editors, decisions made at the update meeting, and changes to the guideline.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Effectiveness of COVID-19 vaccines: findings from real world studies

David A. Henry et al.

Summary: Community-based studies in five countries consistently show strong benefits from early rollouts of COVID-19 vaccines.

MEDICAL JOURNAL OF AUSTRALIA (2021)

添加到收藏夹

Review Oncology

Vaccination of cancer patients against COVID-19: towards the end of a dilemma

Avik Mandal et al.

Summary: With the global emergence of the second wave of COVID-19 infections, vaccination has become crucial. Vaccines have shown to reduce severe illness risk, while cancer patients face added vulnerability to the infection. However, doubts and misconceptions about vaccination during cancer treatment exist.

MEDICAL ONCOLOGY (2021)

添加到收藏夹

Article Economics

Economic value of vaccines to address the COVID-19 pandemic: a US cost-effectiveness and budget impact analysis

William V. Padula et al.

Summary: The study found that COVID-19 vaccines have a high probability of reducing healthcare costs and increasing QALYs compared to doing nothing. It also suggests that investing in vaccines could potentially save up to 60% or more in program costs, with high uptake rates.

JOURNAL OF MEDICAL ECONOMICS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

添加到收藏夹

Article Oncology

Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study

Donna R Rivera et al.

Cancer Discovery (2020)

添加到收藏夹

Article Rheumatology

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Jesus Loarce-Martos et al.

RHEUMATOLOGY INTERNATIONAL (2020)

添加到收藏夹

Review Immunology

What's Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses

Nirupa Gadi et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Oncology

Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies

Kamal S. Saini et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Review Endocrinology & Metabolism

Impact of COVID -19 in cancer patients on severity of disease and fatal outcomes: A systematic review and meta-analysis

Abhijeet Ashok Salunke et al.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2020)

添加到收藏夹

Review Oncology

Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)

C. T. Rieger et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Optimal Timing of Influenza Vaccination During 3-Week Cytotoxic Chemotherapy Cycles

Bhumsuk Keam et al.

CANCER (2017)

添加到收藏夹

Article Medicine, Research & Experimental

Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab

Alice Cho et al.

JCI INSIGHT (2017)

添加到收藏夹

Review Oncology

High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy

Suresh Gopi Kalathil et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)

添加到收藏夹

Review Oncology

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy

Jennifer A. Wargo et al.

SEMINARS IN ONCOLOGY (2015)

添加到收藏夹

Article Immunology

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

Lorry G. Rubin et al.

CLINICAL INFECTIOUS DISEASES (2014)

添加到收藏夹

Article Immunology

Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours

M. L. Wumkes et al.

VACCINE (2013)

添加到收藏夹

Article Oncology

Response to influenza virus vaccination during chemotherapy in patients with breast cancer

A. Meerveld-Eggink et al.

ANNALS OF ONCOLOGY (2011)

添加到收藏夹

Article Nursing

Significant Impairment in Immune Recovery After Cancer Treatment

Duck-Hee Kang et al.

NURSING RESEARCH (2009)

添加到收藏夹

Article Immunology

Effective B cell depletion with rituximab in the treatment of autoimmune diseases

C Kneitz et al.

IMMUNOBIOLOGY (2002)

添加到收藏夹

Article Immunology

Cytokines and hormones as possible links between endocrinosenescence and immunosenescence

RH Straub et al.

JOURNAL OF NEUROIMMUNOLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.